Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$194 Mln
P/E Ratio
--
P/B Ratio
4.68
Industry P/E
--
Debt to Equity
0
ROE
-0.99 %
ROCE
--
Div. Yield
0 %
Book Value
1.74
EPS
-2.2
CFO
$-80.65 Mln
EBITDA
$-124.20 Mln
Net Profit
$-123.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
INmune Bio (INMB)
| 70.24 | -14.52 | 67.37 | -32.68 | 7.39 | 20.73 | -- |
|
BSE Sensex*
| -5.65 | -3.07 | -9.18 | 0.22 | 9.95 | 17.63 | 9.82 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
INmune Bio (INMB)
| -58.23 | 77.60 | -37.84 | -40.77 | 196.90 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.65 | 10,257.64 | 20.82 | 23.13 | |
| 34.62 | 13,507.42 | -- | -28.77 | |
| 110.75 | 11,042.16 | 33.66 | 14.16 | |
| 97.19 | 9,680.89 | 42.64 | 19.71 |
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic... malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432 Read more
Co-Founder, President, CEO, Chief Medical Officer & Chairman
Dr. Raymond Joseph Tesi M.D.
Co-Founder, President, CEO, Chief Medical Officer & Chairman
Dr. Raymond Joseph Tesi M.D.
Headquarters
Boca Raton, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of INmune Bio Inc (INMB) stood at $ 67 Mln as on 30-Sep-24
The share price of INmune Bio Inc (INMB) is $8.77 (NASDAQ) as of 14-Mar-2025 16:01 EDT. INmune Bio Inc (INMB) has given a return of 7.39% in the last 3 years.
INmune Bio Inc (INMB) has a market capitalisation of $ 194 Mln as on 13-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of INmune Bio Inc (INMB) is 4.68 times as on 13-Mar-2025, a 73% premium to its peers’ median range of 2.71 times.
Since, TTM earnings of INmune Bio Inc (INMB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the INmune Bio Inc (INMB) and enter the required number of quantities and click on buy to purchase the shares of INmune Bio Inc (INMB).
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Address: 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
The CEO & director of Dr. Raymond Joseph Tesi M.D.. is INmune Bio Inc (INMB), and CFO & Sr. VP is Dr. Raymond Joseph Tesi M.D..
There is no promoter pledging in INmune Bio Inc (INMB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| INmune Bio Inc. (INMB) | Ratios |
|---|---|
|
Return on equity(%)
|
-121.93
|
|
Operating margin(%)
|
-139407.14
|
|
Net Margin(%)
|
-98266.67
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of INmune Bio Inc (INMB) was $0 Mln.
$0.60
(
